Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment

Autor: van Belzen, Ianthe A E M, Kesmir, Can, Sub Theoretical Biology, Theoretical Biology and Bioinformatics
Přispěvatelé: Sub Theoretical Biology, Theoretical Biology and Bioinformatics
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Adoptive cell transfer
Adoptive cell transfer (ACT)
medicine.medical_treatment
T-Lymphocytes
Immunology
Antigen presentation
Review
Cytokines/analysis
Major histocompatibility complex
03 medical and health sciences
0302 clinical medicine
Immune system
Antigens
Neoplasm
Neoplasms
Neoplasms/immunology
Genetics
medicine
Tumor Microenvironment
Cytotoxic T cell
Humans
Antigens
Antigens
Neoplasm/immunology
Cancer
Neoantigens
Tumor microenvironment
Antigen Presentation
biology
Adoptive Transfer/methods
Neoplasm/immunology
Immunotherapy
T-Lymphocytes
Cytotoxic/immunology
medicine.disease
Adoptive Transfer
3. Good health
030104 developmental biology
Cytotoxic/immunology
Mutation
Cancer research
biology.protein
Cytokines
Tumor Escape
Biomarkers
Biomarkers/blood
030215 immunology
T-Lymphocytes
Cytotoxic
Zdroj: Immunogenetics
Immunogenetics, 71(2), 71. Springer Verlag
ISSN: 0093-7711
DOI: 10.1007/s00251-018-1083-1
Popis: Adoptive cell transfer (ACT) is a form of personalised immunotherapy which has shown promising results in metastasised cancer. For this treatment, autologous T lymphocytes are selected and stimulated in vitro before re-administration in large numbers. However, only a fraction of patients benefit from ACT, and it is not yet known what biomarkers can predict treatment outcome. In this review, we describe what tumour characteristics are associated with response to ACT. Based on the current knowledge, the best candidate biomarker for a good anti-tumour response seems to be a large number of neoantigens with a homogeneous distribution across the tumour in combination with sufficient MHC-I expression level. Additionally, it is necessary to be able to isolate a diverse population of T cells reactive to these neoantigens from tumour tissue or peripheral blood. Additional promising candidate biomarkers shared with other cancer immunotherapies are a large number of tumour-infiltrating cytotoxic and memory T cells, normal levels of glycolysis, and a pro-inflammatory cytokine profile within the tumour. Intense research in this field will hopefully result in identification of more biomarkers for cancers with low mutational load.
Databáze: OpenAIRE
Externí odkaz: